Market Research Logo

Nucleic Acid Testing Market: Nucleic Acid Testing Kits Dominate Led by PCR High Costs Remain a Key Factor Hampering Adoption in Long Run: Global Industry Analysis 2012 -2016 and Opportunity Assessment 2017 - 2027

Nucleic Acid Testing Market: Nucleic Acid Testing Kits Dominate Led by PCR High Costs Remain a Key Factor Hampering Adoption in Long Run: Global Industry Analysis 2012 -2016 and Opportunity Assessment 2017 - 2027

Nucleic Acid Test Kits to Witness Resilient Growth

Nucleic acid testing is widely used to treat infectious diseases caused by virus and bacteria, forensic testing, cancerous diseases, genetically related diseases and paternity testing/HLA typing. The convenience it offers makes it one of the highly preferred testing procedures in the healthcare industry. Nucleic acid tests help in identifying the issue without any previous indications, in addition to offering an additional layer of blood screening and resolving false reactive interpretations. Furthermore, it is an early detection process and is known to provide accurate analysis - faster than any other available procedure, and helps to narrow down infectious period, i.e. window period between the time of viral exposure and the time of serological detection of a virus.

Increasing demand for nucleic acid testing form blood transfusion centers and blood banks will substantially secure the entire blood transfusion processes, which is anticipated to bolster the growth of the global nucleic acid testing market over the forecast period. The global market value is foreseen to reach beyond US$ 4,900 Mn by 2027 end. The market is lucrative, especially for nucleic acid test kits, which is dominated by high demand for polymerase chain reaction (PCR) in the global market. The PCR segment is expected to hold a market value of over US$ 2,300 Mn by the end of 2027, and a cumulative value for the nucleic acid test kits segment is estimated at over US$ 4,400 Mn by the end of forecast period.

Various factors are responsible for forming a favorable market environment for nucleic acid test products

Numerous forces are driving the growth of demand for nucleic acid testing products, which majorly includes the surge in rate of technological development in the healthcare industry. Several companies with extensive product offerings have developed in-house capabilities to generate high-quality products with short turn-around times to meet varying research requirements. Increasing demand for technologically advanced methods in sample preparation, extraction, and amplification and testing for nucleic acids such as DNA and RNA, and the strategic agreements of manufacturers with leading research institutes are expected to boost research activities in the molecular biology field. There is also a broadened scope of nucleic acid testing application globally, as manufacturers of molecular diagnosis devices and kits have been developing several products with the capability to be used in both clinical diagnostics as well as research applications. The increasing demand for advanced technology-based kits in various diagnostic aspects such as infectious diseases, cancer, forensic testing, paternity testing or HLA typing, turns to be the most effective force to facilitate to growth of nucleic acid testing market.

Safety concerns remain longstanding hurdle in market growth

The nucleic acid testing market still faces some limitations in its global demand surge. One of it is the safety concerns associated with the process.The adverse events and false operative functionality associated with the nucleic acid testing kits and reagents may hamper the demand for the product and restrain the growth of the nucleic acid testing market over the forecast period. A few emerging economies lack sophisticated infrastructure required for advanced technologies like nucleic acid testing. The improper development and implementation of clinical practice guidelines and dearth of skilled professionals in most of the countries, such as those in MEA and Latin America, will possibly continue to hinder the growth of the nucleic acid testing market.


1. Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2. Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
2.3. Company Description and Nucleic Acid Testing Market Research Coverage
3. Nucleic Acid Testing Market Opportunity Analysis
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4. Global Economic Outlook
4.1. Global Gross Domestic Product by Region & Country
4.2. Nucleic Acid Testing Market Outlook
5. Market Background
5.1. List of Growth Hacking Manufacturers
5.2. Market Dynamics
5.2.1. Drivers
5.2.2. Restraints
5.3. Regional Pricing Analysis
6. Macroeconomic Assumptions
7. North America Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Regional Market Trends
7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
7.3.1. U.S.
7.3.2. Canada
7.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
7.4.1. U.S.
7.4.2. Canada
7.5. Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
7.5.1. Nucleic Acid test Kits
7.5.1.1. Transcription –mediated amplification (TMA)
7.5.1.2. Polymerase chain reaction (PCR)
7.5.1.3. Ligase chain reaction (LCR)
7.5.1.4. Whole genome sequencing
7.5.2. Consumables
7.6. Market Size (US$ Mn) Forecast By Product Type , 2017-2027
7.7. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
7.7.1. Infectious diseases
7.7.2. Cancer
7.7.3. Forensic Testing
7.7.4. Others
7.8. Market Size (US$ Mn) Forecast By Indication, 2017-2027
7.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
7.9.1. Hospitals
7.9.2. Pathology laboratories
7.9.3. Research Institutes
7.9.4. Clinics
7.10.Market Size (US$ Mn) Forecast By End User, 2017-2027
7.11.Drivers and Restraints: Impact Analysis
7.12.Market Attractiveness Analysis
7.12.1. By Country
7.12.2. By Product Type
7.12.3. By Indication
7.12.4. By End user
7.13.Key Market Participants – Intensity Mapping
7.14.Key Mergers & Acquisitions
8. Western Europe Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Trends
8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
8.3.1. Germany
8.3.2. U.K
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Western Europe
8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
8.4.1. Germany
8.4.2. U.K
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Rest of Western Europe
8.5. Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
8.5.1. Nucleic Acid test Kits
8.5.1.1. Transcription –mediated amplification (TMA)
8.5.1.2. Polymerase chain reaction (PCR)
8.5.1.3. Ligase chain reaction (LCR)
8.5.1.4. Whole genome sequencing
8.5.2. Consumables
8.6. Market Size (US$ Mn) Forecast By Product Type , 2017-2027
8.7. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
8.7.1. Infectious diseases
8.7.2. Cancer
8.7.3. Forensic Testing
8.7.4. Others
8.8. Market Size (US$ Mn) Forecast By Indication, 2017-2027
8.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
8.9.1. Hospitals
8.9.2. Pathology laboratories
8.9.3. Research Institutes
8.9.4. Clinics
8.10.Market Size (US$ Mn) Forecast By End User, 2017-2027
8.11.Drivers and Restraints: Impact Analysis
8.12.Market Attractiveness Analysis
8.12.1. By Country
8.12.2. By Product Type
8.12.3. By Indication
8.12.4. By End user
8.13.Key Market Participants – Intensity Mapping
8.14.Key Mergers & Acquisitions
9. Eastern Europe Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Regional Market Trends
9.3. Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
9.3.1. Russia
9.3.2. Poland
9.3.3. Rest of Eastern Europe
9.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
9.4.1. Russia
9.4.2. Poland
9.4.3. Rest of Eastern Europe
9.5. Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
9.5.1. Nucleic Acid test Kits
9.5.1.1. Transcription –mediated amplification (TMA)
9.5.1.2. Polymerase chain reaction (PCR)
9.5.1.3. Ligase chain reaction (LCR)
9.5.1.4. Whole genome sequencing
9.5.2. Consumables
9.6. Market Size (US$ Mn) Forecast By Product Type , 2017-2027
9.7. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
9.7.1. Infectious diseases
9.7.2. Cancer
9.7.3. Forensic Testing
9.7.4. Others
9.8. Market Size (US$ Mn) Forecast By Indication, 2017-2027
9.9. Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
9.9.1. Hospitals
9.9.2. Pathology laboratories
9.9.3. Research Institutes
9.9.4. Clinics
9.10.Market Size (US$ Mn) Forecast By End User, 2017-2027
9.11.Drivers and Restraints: Impact Analysis
9.12.Market Attractiveness Analysis
9.12.1. By Country
9.12.2. By Product Type
9.12.3. By Indication
9.12.4. By End user
9.13.Key Market Participants – Intensity Mapping
9.14.Key Mergers & Acquisitions
10. Latin America Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
10.1.Introduction
10.2.Regional Market Trends
10.3.Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4.Market Size (US$ Mn) Forecast By Country, 2017-2027
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5.Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
10.5.1. Nucleic Acid test Kits
10.5.1.1. Transcription –mediated amplification (TMA)
10.5.1.2. Polymerase chain reaction (PCR)
10.5.1.3. Ligase chain reaction (LCR)
10.5.1.4. Whole genome sequencing
10.5.2. Consumables
10.6.Market Size (US$ Mn) Forecast By Product Type , 2017-2027
10.7.Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
10.7.1. Infectious diseases
10.7.2. Cancer
10.7.3. Forensic Testing
10.7.4. Others
10.8.Market Size (US$ Mn) Forecast By Indication, 2017-2027
10.9.Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
10.9.1. Hospitals
10.9.2. Pathology laboratories
10.9.3. Research Institutes
10.9.4. Clinics
10.10. Market Size (US$ Mn) Forecast By End User, 2017-2027
10.11. Drivers and Restraints: Impact Analysis
10.12. Market Attractiveness Analysis
10.12.1. By Country
10.12.2. By Product Type
10.12.3. By Indication
10.12.4. By End user
10.13. Key Market Participants – Intensity Mapping
10.14. Key Mergers & Acquisitions
11. Asia Pacific Excluding China & Japan Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
11.1.Introduction
11.2.Regional Market Trends
11.3.Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
11.3.1. India
11.3.2. Australia and New Zealand
11.3.3. ASEAN
11.3.4. Rest of APECJ
11.4.Market Size (US$ Mn) Forecast By Country, 2017-2027
11.4.1. India
11.4.2. Australia and New Zealand
11.4.3. ASEAN
11.4.4. Rest of APECJ
11.5.Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
11.5.1. Nucleic Acid test Kits
11.5.1.1. Transcription –mediated amplification (TMA)
11.5.1.2. Polymerase chain reaction (PCR)
11.5.1.3. Ligase chain reaction (LCR)
11.5.1.4. Whole genome sequencing
11.5.2. Consumables
11.6.Market Size (US$ Mn) Forecast By Product Type , 2017-2027
11.7.Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
11.7.1. Infectious diseases
11.7.2. Cancer
11.7.3. Forensic Testing
11.7.4. Others
11.8.Market Size (US$ Mn) Forecast By Indication, 2017-2027
11.9.Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
11.9.1. Hospitals
11.9.2. Pathology laboratories
11.9.3. Research Institutes
11.9.4. Clinics
11.10. Market Size (US$ Mn) Forecast By End User, 2017-2027
11.11. Drivers and Restraints: Impact Analysis
11.12. Market Attractiveness Analysis
11.12.1. By Country
11.12.2. By Product Type
11.12.3. By Indication
11.12.4. By End user
11.13. Key Market Participants – Intensity Mapping
11.14. Key Mergers & Acquisitions
12. China Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
12.1.Introduction
12.2.Market Trends
12.3.Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
12.3.1. Nucleic Acid test Kits
12.3.1.1. Transcription –mediated amplification (TMA)
12.3.1.2. Polymerase chain reaction (PCR)
12.3.1.3. Ligase chain reaction (LCR)
12.3.1.4. Whole genome sequencing
12.3.2. Consumables
12.4.Market Size (US$ Mn) Forecast By Product Type , 2017-2027
12.5.Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
12.5.1. Infectious diseases
12.5.2. Cancer
12.5.3. Forensic Testing
12.5.4. Others
12.6.Market Size (US$ Mn) Forecast By Indication, 2017-2027
12.7.Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
12.7.1. Hospitals
12.7.2. Pathology laboratories
12.7.3. Research Institutes
12.7.4. Clinics
12.8.Market Size (US$ Mn) Forecast By End User, 2017-2027
12.9.Drivers and Restraints: Impact Analysis
12.10. Market Attractiveness Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Indication
12.10.4. By End user
12.11. Key Market Participants – Intensity Mapping
12.12. Key Mergers & Acquisitions
13. Japan Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
13.1.Introduction
13.2.Market Trends
13.3.Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
13.3.1. Nucleic Acid test Kits
13.3.1.1. Transcription –mediated amplification (TMA)
13.3.1.2. Polymerase chain reaction (PCR)
13.3.1.3. Ligase chain reaction (LCR)
13.3.1.4. Whole genome sequencing
13.3.2. Consumables
13.4.Market Size (US$ Mn) Forecast By Product Type , 2017-2027
13.5.Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
13.5.1. Infectious diseases
13.5.2. Cancer
13.5.3. Forensic Testing
13.5.4. Others
13.6.Market Size (US$ Mn) Forecast By Indication, 2017-2027
13.7.Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
13.7.1. Hospitals
13.7.2. Pathology laboratories
13.7.3. Research Institutes
13.7.4. Clinics
13.8.Market Size (US$ Mn) Forecast By End User, 2017-2027
13.9.Drivers and Restraints: Impact Analysis
13.10. Market Attractiveness Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Indication
13.10.4. By End user
13.11. Key Market Participants – Intensity Mapping
13.12. Key Mergers & Acquisitions
14. Middle East and Africa Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027
14.1.Introduction
14.2.Regional Market Trends
14.3.Historical Market Size (US$ Mn) Analysis By Country, 2012-2016
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4.Market Size (US$ Mn) Forecast By Country, 2017-2027
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East and Africa
14.5.Historical Market Size (US$ Mn) Analysis By Product Type , 2012-2016
14.5.1. Nucleic Acid test Kits
14.5.1.1. Transcription –mediated amplification (TMA)
14.5.1.2. Polymerase chain reaction (PCR)
14.5.1.3. Ligase chain reaction (LCR)
14.5.1.4. Whole genome sequencing
14.5.2. Consumables
14.6.Market Size (US$ Mn) Forecast By Product Type , 2017-2027
14.7.Historical Market Size (US$ Mn) Trend Analysis By Indication, 2012-2016
14.7.1. Infectious diseases
14.7.2. Cancer
14.7.3. Forensic Testing
14.7.4. Others
14.8.Market Size (US$ Mn) Forecast By Indication, 2017-2027
14.9.Historical Market Size (US$ Mn) Trend Analysis By End User, 2012-2016
14.9.1. Hospitals
14.9.2. Pathology laboratories
14.9.3. Research Institutes
14.9.4. Clinics
14.10. Market Size (US$ Mn) Forecast By End User, 2017-2027
14.11. Drivers and Restraints: Impact Analysis
14.12. Market Attractiveness Analysis
14.12.1. By Country
14.12.2. By Product Type
14.12.3. By Indication
14.12.4. By End user
14.13. Key Market Participants – Intensity Mapping
14.14. Key Mergers & Acquisitions
15. Forecast Factors: Relevance and Impact
16. Forecast Assumptions
17. Market Structure Analysis
17.1.Market Structure by Tier of Companies
17.2.Market Share Analysis (2016) for Top 10 Players, By Region
18. Competition Analysis
18.1.Competition Dashboard
18.2.Profitability and Gross Margin Analysis By Competition
18.3.Company Deep Dive
18.3.1. Agilent Technologies
18.3.1.1. Overview
18.3.1.2. Product and Application Portfolio
18.3.1.3. Production Footprint
18.3.1.4. Sales Footprint
18.3.1.5. Channel Footprint
18.3.1.6. Strategy
18.3.1.6.1. Marketing Strategy
18.3.1.6.2. Product Strategy
18.3.1.6.3. Channel Strategy
18.3.2. Danaher Corporation
18.3.2.1. Overview
18.3.2.2. Product and Application Portfolio
18.3.2.3. Production Footprint
18.3.2.4. Sales Footprint
18.3.2.5. Channel Footprint
18.3.2.6. Strategy
18.3.2.6.1. Marketing Strategy
18.3.2.6.2. Product Strategy
18.3.2.6.3. Channel Strategy
18.3.3. Abbott Laboratories, Inc.
18.3.3.1. Overview
18.3.3.2. Product and Application Portfolio
18.3.3.3. Production Footprint
18.3.3.4. Sales Footprint
18.3.3.5. Channel Footprint
18.3.3.6. Strategy
18.3.3.6.1. Marketing Strategy
18.3.3.6.2. Product Strategy
18.3.3.6.3. Channel Strategy
18.3.4. Becton, Dickinson and Company
18.3.4.1. Overview
18.3.4.2. Product and Application Portfolio
18.3.4.3. Production Footprint
18.3.4.4. Sales Footprint
18.3.4.5. Channel Footprint
18.3.4.6. Strategy
18.3.4.6.1. Marketing Strategy
18.3.4.6.2. Product Strategy
18.3.4.6.3. Channel Strategy
18.3.5. Bio-Rad Laboratories, Inc.
18.3.5.1. Overview
18.3.5.2. Product and Application Portfolio
18.3.5.3. Production Footprint
18.3.5.4. Sales Footprint
18.3.5.5. Channel Footprint
18.3.5.6. Strategy
18.3.5.6.1. Marketing Strategy
18.3.5.6.2. Product Strategy
18.3.5.6.3. Channel Strategy
18.3.6. F. Hoffmann-La Roche Ltd.
18.3.6.1. Overview
18.3.6.2. Product and Application Portfolio
18.3.6.3. Production Footprint
18.3.6.4. Sales Footprint
18.3.6.5. Channel Footprint
18.3.6.6. Strategy
18.3.6.6.1. Marketing Strategy
18.3.6.6.2. Product Strategy
18.3.6.6.3. Channel Strategy
18.3.7. Illumina, Inc.
18.3.7.1. Overview
18.3.7.2. Product and Application Portfolio
18.3.7.3. Production Footprint
18.3.7.4. Sales Footprint
18.3.7.5. Channel Footprint
18.3.7.6. Strategy
18.3.7.6.1. Marketing Strategy
18.3.7.6.2. Product Strategy
18.3.7.6.3. Channel Strategy
18.3.8. Thermo Fisher Scientific Inc.
18.3.8.1. Overview
18.3.8.2. Product and Application Portfolio
18.3.8.3. Production Footprint
18.3.8.4. Sales Footprint
18.3.8.5. Channel Footprint
18.3.8.6. Strategy
18.3.8.6.1. Marketing Strategy
18.3.8.6.2. Product Strategy
18.3.8.6.3. Channel Strategy
18.3.9. Merck KGaA,
18.3.9.1. Overview
18.3.9.2. Product and Application Portfolio
18.3.9.3. Production Footprint
18.3.9.4. Sales Footprint
18.3.9.5. Channel Footprint
18.3.9.6. Strategy
18.3.9.6.1. Marketing Strategy
18.3.9.6.2. Product Strategy
18.3.9.6.3. Channel Strategy
18.3.10. Qiagen
18.3.10.1. Overview
18.3.10.2. Product and Application Portfolio
18.3.10.3. Production Footprint
18.3.10.4. Sales Footprint
18.3.10.5. Channel Footprint
18.3.10.6. Strategy
18.3.10.6.1. Marketing Strategy
18.3.10.6.2. Product Strategy
18.3.10.6.3. Channel Strategy
19. Global Nucleic Acid Testing Market Analysis 2012–2016 and Forecast 2017–2027 By Region
19.1.Introduction / Key Findings
19.2.Historical Market Size (US$ Mn) Analysis By Region
19.2.1. North America
19.2.2. Western Europe
19.2.3. Eastern Europe
19.2.4. Latin America
19.2.5. Asia Pacific Excluding Japan
19.2.6. Japan
19.2.7. Middle East and Africa
19.3.Market Size (US$ Mn) Forecast By Region
19.3.1. North America
19.3.2. Western Europe
19.3.3. Eastern Europe
19.3.4. Latin America
19.3.5. Asia Pacific Excluding Japan
19.3.6. Japan
19.3.7. Middle East and Africa
19.4.Market Attractiveness Analysis By Region

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report